AI assistant
ENLITIC INC. — M&A Activity 2024
Oct 16, 2024
64853_rns_2024-10-16_fe71c43f-668e-4f37-9b83-40a7903c96d8.pdf
M&A Activity
Open in viewerOpens in your device viewer
ASX Announcement
==> picture [136 x 35] intentionally omitted <==
17 October 2024
Laitek acquisition completes
Enlitic, Inc. (ASX: ENL) (“the Company” or “Enlitic”) announced on Thursday, 29 August 2024 that it had signed binding conditional documentation to acquire 100% of the shares in Laitek Inc. (“Laitek Acquisition”).
Enlitic is pleased to announce that the Laitek Acquisition has now completed.
For further information in respect of the Laitek Acquisition please refer to the Company’s ASX announcements dated Thursday, 29 August 2024 and Monday, 2 September 2024.
– ENDS –
This announcement was authorised for release by the Board of Enlitic, Inc.
Enquiries
Enlitic Investor Relations
Australia: [email protected]
About Enlitic
manage medical imaging data in radiology (such as MRI, CT scans, X-ray and ultrasound images) and licences such products to healthcare providers. Enlitic’s products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that can improve clinical workflows, increase efficiencies, and expand capacity. Read more at enlitic.com.
Enlitic’s CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933 as amended, and in accordance with the procedures established pursuant to the provisions of a no action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this announcement.
Enli�c, Inc. ARBN 672 254 027
1